TLR4 activation enhances the PD-L1-mediated tolerogenic capacity of colonic CD90+stromal cells

Journal of Immunology

Volumn 193, Issue 5, 2014, Pages 2218-2229

  Beswick, Ellen J ^a   Johnson, Jameel R ^b   Saada, Jamal I ^b   Humen, Martin ^b   House, Jenifer ^b   Dann, Sara ^b   Qiu, Suimin ^b   Brasier, Allan R ^b,c   Powell, Don W ^b,c   Reyes, Victor E ^b,c   Pinchuk, Irina V ^b,c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 2; MYELOID DIFFERENTIATION FACTOR 88; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; THY 1 ANTIGEN; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; CD274 PROTEIN, HUMAN; CD274 PROTEIN, MOUSE; IFNG PROTEIN, HUMAN; MYD88 PROTEIN, HUMAN; MYD88 PROTEIN, MOUSE; TLR4 PROTEIN, HUMAN; TLR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL SPECIFICITY; COLON INJURY; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTESTINE CELL; KNOCKOUT MOUSE; LYMPHOCYTE PROLIFERATION; MOUSE; MYOFIBROBLAST; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; STROMA CELL; UPREGULATION; ANIMAL; CLINICAL TRIAL; COLON; CYTOLOGY; FEMALE; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INTESTINE MUCOSA; MALE; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD274; ANTIGENS, THY-1; COLON; FEMALE; HUMANS; IMMUNE TOLERANCE; INTERFERON-GAMMA; INTESTINAL MUCOSA; MALE; MICE; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; MYOFIBROBLASTS; STROMAL CELLS; TOLL-LIKE RECEPTOR 4; UP-REGULATION;

EID: 84907026877     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203441     Document Type: Article

References (72)

1. Untersmayr, E., and E. Jensen-Jarolim. 2006. Mechanisms of type I food allergy. Pharmacol. Ther. 112: 787-798.
2. Tannock, G.W. 1999. Probiotics: A Critical Review.Wymondham: Horizon Scientific Ed.
3. Novak, N., J. Haberstok, T. Bieber, and J. P. Allam. 2008. The immune privilege of the oral mucosa. Trends Mol. Med. 14: 191-198.
4. Ricanek, P., S. M. Lothe, S. A. Frye, A. Rydning, M. H. Vatn, and T. Tonjum. 2012. Gut bacterial profile in patients newly diagnosed with treatment-naivë Crohn's disease. Clin. Exp. Gastroenterol. 5: 173-186.
5. Zhang, Z., J. Geng, X. Tang, H. Fan, J. Xu, X. Wen, Z. S. Ma, and P. Shi. 2014. Spatial heterogeneity and co-occurrence patterns of human mucosal-associated intestinal microbiota. ISME J. 8: 881-893.
6. Reynoso, E. D., K. G. Elpek, L. Francisco, R. Bronson, A. Bellemare-Pelletier, A. H. Sharpe, G. J. Freeman, and S. J. Turley. 2009. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J. Immunol. 182: 2102-2112.
7. Francisco, L. M., P. T. Sage, and A. H. Sharpe. 2010. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236: 219-242.
8. Jiang, X., J. Zhou, A. Giobbie-Hurder, J. Wargo, and F. S. Hodi. 2013. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin. Cancer Res. 19: 598-609.
9. Rozali, E. N., S. V. Hato, B. W. Robinson, R. A. Lake, and W. J. Lesterhuis. 2012. Programmed death ligand 2 in cancer-induced immune suppression. Clin. Dev. Immunol. 2012: 656340.
10. Podojil, J. R., and S. D. Miller. 2013. Targeting the B7 family of co-stimulatory molecules: successes and challenges. BioDrugs 27: 1-13.
11. Loke, P., and J. P. Allison. 2003. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. USA 100: 5336-5341.
12. D'Addio, F., L. V. Riella, B. G. Mfarrej, L. Chabtini, L. T. Adams, M. Yeung, H. Yagita, M. Azuma, M. H. Sayegh, and I. Guleria. 2011. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J. Immunol. 187: 4530-4541.
13. Amarnath, S., C.W. Mangus, J.C. Wang, F. Wei, A. He, V. Kapoor, J.E. Foley, P.R. Massey, T.C. Felizardo, J.L. Riley, et al. 2011. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci. Transl. Med. 3: 111ra20.
14. Keir, M. E., S. C. Liang, I. Guleria, Y. E. Latchman, A. Qipo, L. A. Albacker, M. Koulmanda, G. J. Freeman, M. H. Sayegh, and A. H. Sharpe. 2006. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203: 883-895.
15. Nakazawa, A., I. Dotan, J. Brimnes, M. Allez, L. Shao, F. Tsushima, M. Azuma, and L. Mayer. 2004. The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology 126: 1347-1357.
16. Kanai, T., T. Totsuka, K. Uraushihara, S. Makita, T. Nakamura, K. Koganei, T. Fukushima, H. Akiba, H. Yagita, K. Okumura, et al. 2003. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J. Immunol. 171: 4156-4163.
17. Pinchuk, I. V., J. I. Saada, E. J. Beswick, G. Boya, S. M. Qiu, R. C. Mifflin, G. S. Raju, V. E. Reyes, and D. W. Powell. 2008. PD-1 ligand expression by human colonic myofibroblasts/fibroblasts regulates CD4+ T-cell activity. Gastroenterology 135: 1228-1237.
18. Saada, J. I., I. V. Pinchuk, C. A. Barrera, P. A. Adegboyega, G. Suarez, R. C. Mifflin, J. F. Di Mari, V. E. Reyes, and D. W. Powell. 2006. Subepithelial myofibroblasts are novel nonprofessional APCs in the human colonic mucosa. J. Immunol. 177: 5968-5979.
19. Owens, B. M., T. A. Steevels, M. Dudek, D. Walcott, M. Y. Sun, A. Mayer, P. Allan, and A. Simmons. 2013. CD90(+) Stromal Cells are Non-Professional Innate Immune Effectors of the Human Colonic Mucosa. Front. Immunol. 4: 307.
20. Park, J. J., R. Omiya, Y. Matsumura, Y. Sakoda, A. Kuramasu, M. M. Augustine, S. Yao, F. Tsushima, H. Narazaki, S. Anand, et al. 2010. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 116: 1291-1298.
21. Powell, D. W., I. V. Pinchuk, J. I. Saada, X. Chen, and R. C. Mifflin. 2011. Mesenchymal cells of the intestinal lamina propria. Annu. Rev. Physiol. 73: 213-237.
22. Månsson, L. E., M. Montero, M. Zarepour, K. S. Bergstrom, C. Ma, T. Huang, C. Man, G. A. Grassl, and B. A. Vallance. 2012. MyD88 signaling promotes both mucosal homeostatic and fibrotic responses during Salmonella-induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 303: G311-G323.
23. Fukata, M., and M. Arditi. 2013. The role of pattern recognition receptors in intestinal inflammation. Mucosal Immunol. 6: 451-463.
24. Burke, J. P., M. F. Cunningham, R. W. Watson, N. G. Docherty, J. C. Coffey, and P. R. O'Connell. 2010. Bacterial lipopolysaccharide promotes profibrotic activation of intestinal fibroblasts. Br. J. Surg. 97: 1126-1134.
25. Kamdar, K., V. Nguyen, and R. W. DePaolo. 2013. Toll-like receptor signaling and regulation of intestinal immunity. Virulence 4: 207-212.
26. Maynard, C. L., C. O. Elson, R. D. Hatton, and C. T. Weaver. 2012. Reciprocal interactions of the intestinal microbiota and immune system. Nature 489: 231-241.
27. Otte, J. M., I. M. Rosenberg, and D. K. Podolsky. 2003. Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology 124: 1866-1878.
28. Allam, J. P., W. M. Peng, T. Appel, M. Wenghoefer, B. Niederhagen, T. Bieber, S. Bergé, and N. Novak. 2008. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J. Allergy Clin. Immunol. 121: 368- 374, e1.
29. Bao, H., P. Lu, Y. Li, L. Wang, H. Li, D. He, Y. Yang, Y. Zhao, L. Yang, M. Wang, et al. 2011. Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack. Cancer Biol. Ther. 11: 58-67.
30. Berthon, C., V. Driss, J. Liu, K. Kuranda, X. Leleu, N. Jouy, D. Hetuin, and B. Quesnel. 2010. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol. Immunother. 59: 1839-1849.
31. Owens, B. M., and A. Simmons. 2013. Intestinal stromal cells in mucosal immunity and homeostasis. Mucosal Immunol. 6: 224-234.
32. Mahida, Y. R., J. Beltinger, S. Makh, M. Göke, T. Gray, D. K. Podolsky, and C. J. Hawkey. 1997. Adult human colonic subepithelial myofibroblasts express extracellular matrix proteins and cyclooxygenase-1 and -2. Am. J. Physiol. 273: G1341-G1348.
33. Zheng, B., Z. Zhang, C. M. Black, B. de Crombrugghe, and C. P. Denton. 2002. Ligand-dependent genetic recombination in fibroblasts : a potentially powerful technique for investigating gene function in fibrosis. Am. J. Pathol. 160: 1609-1617.
34. Wirtz, S., C. Neufert, B. Weigmann, and M. F. Neurath. 2007. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2: 541-546.
35. Pinchuk, I. V., E. J. Beswick, J. I. Saada, G. Boya, D. Schmitt, G. S. Raju, J. Brenmoehl, G. Rogler, V. E. Reyes, and D. W. Powell. 2011. Human colonic myofibroblasts promote expansion of CD4+ CD25high Foxp3+ regulatory T cells. Gastroenterology 140: 2019-2030.
36. Abreu, M. T., M. Fukata, and M. Arditi. 2005. TLR signaling in the gut in health and disease. J. Immunol. 174: 4453-4460.
37. Walton, K. L., L. Holt, and R. B. Sartor. 2009. Lipopolysaccharide activates innate immune responses in murine intestinal myofibroblasts through multiple signaling pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G601-G611.
38. Seki, E., and B. Schnabl. 2012. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J. Physiol. 590: 447-458.
39. Chen, L., and D. B. Flies. 2013. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13: 227-242.
40. Latchman, Y. E., S. C. Liang, Y. Wu, T. Chernova, R. A. Sobel, M. Klemm, V. K. Kuchroo, G. J. Freeman, and A. H. Sharpe. 2004. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl. Acad. Sci. USA 101: 10691-10696.
41. Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8: 793-800.
42. Venkatachari, N. J., W. G. Buchanan, and V. Ayyavoo. 2008. Human immunodeficiency virus (HIV-1) infection selectively downregulates PD-1 expression in infected cells and protects the cells from early apoptosis in vitro and in vivo. Virology 376: 140-153.
43. Wei, S., A. B. Shreiner, N. Takeshita, L. Chen, W. Zou, and A. E. Chang. 2008. Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer Res. 68: 5432-5438.
44. Jones, E., I. M. Adcock, B. Y. Ahmed, and N. A. Punchard. 2007. Modulation of LPS stimulated NF-kappaB mediated Nitric Oxide production by PKCepsilon and JAK2 in RAW macrophages. J. Inflamm. (Lond.) 4: 23.
45. Burdelya, L., R. Catlett-Falcone, A. Levitzki, F. Cheng, L. B. Mora, E. Sotomayor, D. Coppola, J. Sun, S. Sebti, W. S. Dalton, et al. 2002. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol. Cancer Ther. 1: 893-899.
46. Meydan, N., T. Grunberger, H. Dadi, M. Shahar, E. Arpaia, Z. Lapidot, J. S. Leeder, M. Freedman, A. Cohen, A. Gazit, et al. 1996. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379: 645-648.
47. Abe, M., M. Funakoshi-Tago, K. Tago, J. Kamishimoto, E. Aizu-Yokota, Y. Sonoda, and T. Kasahara. 2009. The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice. Int. Immunopharmacol. 9: 870-877.
48. Marienfeld, R., M. J. May, I. Berberich, E. Serfling, S. Ghosh, and M. Neumann. 2003. RelB forms transcriptionally inactive complexes with RelA/p65. J. Biol. Chem. 278: 19852-19860.
49. Jacque, E., T. Tchenio, G. Piton, P. H. Romeo, and V. Baud. 2005. RelA repression of RelB activity induces selective gene activation downstream of TNF receptors. Proc. Natl. Acad. Sci. USA 102: 14635-14640.
50. Mukherjee, S., L. Y. Chen, T. J. Papadimos, S. Huang, B. L. Zuraw, and Z. K. Pan. 2009. Lipopolysaccharide-driven Th2 cytokine production in macrophages is regulated by both MyD88 and TRAM. J. Biol. Chem. 284: 29391-29398.
51. Liu, J., A. Hamrouni, D. Wolowiec, V. Coiteux, K. Kuliczkowski, D. Hetuin, A. Saudemont, and B. Quesnel. 2007. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-gamma and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110: 296-304.
52. Meier, A., A. Bagchi, H. K. Sidhu, G. Alter, T. J. Suscovich, D. G. Kavanagh, H. Streeck, M. A. Brockman, S. LeGall, J. Hellman, and M. Altfeld. 2008. Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands. AIDS 22: 655-658.
53. Li, G., D. Liu, Y. Zhang, Y. Qian, H. Zhang, S. Guo, M. Sunagawa, T. Hisamitsu, and Y. Liu. 2013. Celastrol inhibits lipopolysaccharide-stimulated rheumatoid fibroblast-like synoviocyte invasion through suppression of TLR4/NF-kBmediated matrix metalloproteinase-9 expression. PLoS ONE 8: e68905.
54. Rothstein, D. M. 2006. Immunosuppression and regulation: cast in new light? J. Am. Soc. Nephrol. 17: 2644-2646.
55. Halloran, P. F., J. Bromberg, B. Kaplan, and F. Vincenti. 2008. Tolerance versus immunosuppression: a perspective. Am. J. Transplant. 8: 1365-1366.
56. Pabst, O., and A. M. Mowat. 2012. Oral tolerance to food protein. Mucosal Immunol. 5: 232-239.
57. Kuhn, K. A., and T. S. Stappenbeck. 2013. Peripheral education of the immune system by the colonic microbiota. Semin. Immunol. 25: 364-369.
58. Kirkland, D., A. Benson, J. Mirpuri, R. Pifer, B. Hou, A. L. DeFranco, and F. Yarovinsky. 2012. B cell-intrinsic MyD88 signaling prevents the lethal dissemination of commensal bacteria during colonic damage. Immunity 36: 228-238.
59. Jones, S., N. Horwood, A. Cope, and F. Dazzi. 2007. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J. Immunol. 179: 2824-2831.
60. Saada, J. I., C. A. Barrera, V. E. Reyes, P. A. Adegboyega, G. Suarez, R. A. Tamerisa, K. F. Pang, D. A. Bland, R. C. Mifflin, J. F. DI Mari, and D. W. Powell. 2004. Intestinal myofibroblasts and immune tolerance. Ann. N. Y. Acad. Sci. 1029: 379-381.
61. Lee, S. K., S. H. Seo, B. S. Kim, C. D. Kim, J. H. Lee, J. S. Kang, P. J. Maeng, and J. S. Lim. 2005. IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells. J. Dermatol. Sci. 40: 95-103.
62. Wölfle, S. J., J. Strebovsky, H. Bartz, A. Sähr, C. Arnold, C. Kaiser, A. H. Dalpke, and K. Heeg. 2011. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur. J. Immunol. 41: 413-424.
63. Rogler, G., C. M. Gelbmann, D. Vogl, M. Brunner, J. Schölmerich, W. Falk, T. Andus, and K. Brand. 2001. Differential activation of cytokine secretion in primary human colonic fibroblast/myofibroblast cultures. Scand. J. Gastroenterol. 36: 389-398.
64. Green, M. R., S. Monti, S. J. Rodig, P. Juszczynski, T. Currie, E. O'Donnell, B. Chapuy, K. Takeyama, D. Neuberg, T. R. Golub, et al. 2010. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116: 3268-3277.
65. Mahanonda, R., N. Sa-Ard-Iam, P. Montreekachon, A. Pimkhaokham, K. Yongvanichit, M. M. Fukuda, and S. Pichyangkul. 2007. IL-8 and IDO expression by human gingival fibroblasts via TLRs. J. Immunol. 178: 1151-1157.
66. Rakoff-Nahoum, S., J. Paglino, F. Eslami-Varzaneh, S. Edberg, and R. Medzhitov. 2004. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118: 229-241.
67. Rakoff-Nahoum, S., and R. Medzhitov. 2007. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317: 124-127.
68. Schiechl, G., B. Bauer, I. Fuss, S. A. Lang, C. Moser, P. Ruemmele, S. Rose- John, M. F. Neurath, E. K. Geissler, H. J. Schlitt, et al. 2011. Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+ CD11b(high)Gr1(low) macrophages. J. Clin. Invest. 121: 1692-1708.
69. Brahmer, J. R., S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366: 2455-2465.
70. Brahmer, J. R. 2012. PD-1-targeted immunotherapy: recent clinical findings. Clin. Adv. Hematol. Oncol. 10: 674-675.
71. Brahmer, J. R., C. G. Drake, I. Wollner, J. D. Powderly, J. Picus, W. H. Sharfman, E. Stankevich, A. Pons, T. M. Salay, T. L. McMiller, et al. 2010. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28: 3167-3175.
72. Lozupone, C. A., J. I. Stombaugh, J. I. Gordon, J. K. Jansson, and R. Knight. 2012. Diversity, stability and resilience of the human gut microbiota. Nature 489: 220-230.